HR and breast carcinoma: Furthermore, the MonarchE study revealed that incorporating Aemaciclib into adjuvant endocrine therapy significantly enhanced invasive disease-free survival in patients with HR + /HER2-, node-positive, high-risk early breast cancer, while maintaining an acceptable safety profile.